Alaunos Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
Strategic EP, LLC has reported a complete divestment of its beneficial ownership in Alaunos Therapeutics, Inc., now holding 0% of the common stock as of October 14, 2025.
NASDAQ
Strategic EP, LLC has reported a 6.8% beneficial ownership stake in Alaunos Therapeutics, Inc., alongside a standstill agreement that limits its influence.
NASDAQ
SCHEDULE 13G/A: MSD Partners and Affiliates Divest Entire Stake in Alaunos Therapeutics, Reporting Zero Beneficial Ownership
MSD Partners, MSD Credit Opportunity Master Fund, and Gregg R. Lemkau have filed an Amendment No. 5 to Schedule 13G, disclosing that they no longer beneficially own any shares of Alaunos Therapeutics, Inc. common stock.